Recognising Neurofibromatosis Type 1 (NF1)

Recognising Neurofibromatosis Type 1 (NF1)
A CPD Training Module for Health Professionals
Course Duration: 1 hour
Accreditation: CPD pending
Provider: Childhood Tumour Trust
Early recognition of Neurofibromatosis Type 1 (NF1) is essential for improving outcomes, reducing complications, and ensuring patients receive appropriate monitoring and support. This free CPD module equips healthcare professionals with the knowledge to identify key signs, apply diagnostic criteria, and support families affected by NF1.
This CPD module discusses neurofibromatosis type 1 – a rare disease that has many clinical manifestations. It is essential reading for all health professionals, particularly those working in:
- Diagnosis & Monitoring
- Medical Management & Treatment
- Surgical & Procedural Disciplines
- Allied Health, Education & Support
- Anyone with an interest in rare diseases.
Learning Outcomes
After completing this course, you will be able to:
• Understand the genetic basis and clinical presentation of NF1
• Recognise hallmark signs such as café-au-lait spots, axillary/groin freckling & neurofibromas
• Identify complications associated with NF1
• Apply diagnostic criteria in children and adults
• Provide guidance to parents and newly-diagnosed adults
• Know when and where to refer for specialist assessment
Course Format
This self-directed online module consists of:
• Downloadable CPD-accredited NF1 training guide
• Structured learning lessons
• A self-assessment quiz
• Certificate issued upon successful completion
How to Complete the Module
- Work through each lesson
- Read the downloadable NF1 PDF
- Complete the self-assessment quiz
- Score 80% or above to receive your certificate
Start the Module
Click ‘Take This Course’ to begin.
Written* by: Diane Lace BSc (Hons), PhD
Reviewed by:
Dr Jude Hayward MRCP MRCGP DRCOG MSc (Genomic Medicine) GP/GPwER
Leeds Clinical Genomics Service and Primary Care Lead NHSE Genomics Education Programme
Dr Will Evans MSc MRCGP, GP and GPwER Leeds Clinical Genomics Service
*Contains content reproduced from material written by Kristina Routh MBChB, MPH
© 2025 Childhood Tumour Trust